Efficacy and safety of second-generation long-acting injections in schizophrenia: A meta-analysis of randomized-controlled trials

International Clinical Psychopharmacology

Volumn 28, Issue 2, 2013, Pages 57-66

  Fusar Poli, Paolo ^a   Kempton, Matthew J ^a   Rosenheck, Robert A ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

long acting injections; psychosis; schizophrenia; second generation antipsychotic injections

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ANXIETY; DEMOGRAPHY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; INJECTION PAIN; INSOMNIA; MAJOR CLINICAL STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PUBLISHING; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; EVIDENCE-BASED MEDICINE; EXTRAPYRAMIDAL TRACTS; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA;

EID: 84873406846     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32835b091f     Document Type: Review

References (48)

1. Adams CE, Fenton MK, Quraishi S, David AS (2001). Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 179:290-299.
2. Adams CE, Awad G, Rathbone J, Thornley B (2007). Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev CD000284.
3. Aggarwal NK, Sernyak MJ, Rosenheck RA (2012). Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting intramuscular antipsychotic medications. J Clin Psychopharmacol 32:323-328.
4. Bai YM, Ting Chen T, Chen JY, Chang WH, Wu B, Hung CH, Kuo Lin W (2007). Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry 68:1218-1225.
5. Barnett PG, Scott J, Krystal JY, Rosenheck RA (2012). Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry 73:696-702.
6. Barnett P, Scott J, Rosenheck R (2011). How do clinical trial participants compare to other patients with schizophrenia? Schizophr Res 130:34-39.
7. Borenstein M, Haa L, Higgins J, Rothstein H (2005). Comprehensive meta-analysis version 2. Englewood, NJ, USA: Biostat.
8. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. (2005). Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 15:111-117.
9. De Arce Cordon R, Eding E, Marques-Teixeira J, Milanova V, Rancans E, Schreiner A (2011). Descriptive analyses of the aripiprazole arm in the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Eur Arch Psychiatry Clin Neurosci 262:139-149. Epub 2011 August 2.
10. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629-634.
11. Finniss DG, Kaptchuk TJ, Miller F, Benedetti F (2010). Biological, clinical, and ethical advances of placebo effects. Lancet 375:686-695.
12. Fleischhacker WW (2009). Second-generation antipsychotic long-acting injections: systematic review. Br J Psychiatry Suppl 52:S29-S36.
13. Gaebel W, Schreiner A, Bergmans P, de Arce R, Rouillon F, Cordes J, et al. (2010). Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial. Neuropsychopharmacology 35:2367-2377.
14. Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M (2010). Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr Res 116:107-117.
15. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. (2006). Randomized controlled trial of the effect on quality of life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079-1087.
16. Joy CB, Adams CE, Lawrie SM (2006). Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev CD003082.
17. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 371:1085-1097.
18. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K (2003a). Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125-1132.
19. Kane JM, Leucht S, Carpenter D, Docherty JP (2003b). The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64 (Suppl 12):5-19.
20. Kane JM, Detke HC, Naber D, Sethuraman G, Lin DY, Bergstrom RF, McDonnell D (2010). Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry 167:181-189.
21. Keks NA, Ingham M, Khan A, Karcher K (2007). Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 191:131-139.
22. Kempton MJ, Stahl D, Williams SC, DeLisi LE (2010). Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies Schizophr Res 120:54-62.
23. Kraemer HC, Kupfer DJ (2006). Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 59:990-996.
24. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M (2010). Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 13:635-647.
25. Lauriello J, Lambert T, Andersen S, Lin D, Taylor CC, McDonnell D (2008). An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 69:790-799.
26. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (2009a). How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 14:429-447.
27. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (2009b). Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373:31-41.
28. Leucht S, Davis JM, Engel RR, Kissling W, Kane JM (2009c). Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr Scand Suppl 7-14.
29. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, et al. (2009d). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 166:152-163.
30. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S (2011). Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res 127:83-92.
31. Lieberman JA, Phillips M, Gu H, Stroup S, Zhang P, Kong L, et al. (2003). Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 28:995-1003.
32. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223.
33. Lipsey M, Wilson D (2000). Practical meta-analysis. Thousand Oaks, CA: Sage Publications.
34. Macfadden W, Ma YW, Thomas Haskins J, Bossie CA, Alphs L (2010). A prospective study comparing the long-term effectiveness of injectable risperidone long-acting therapy and oral aripiprazole in patients with schizophrenia. Psychiatry (Edgmont) 7:23-31.
35. Mattis P, Kimball S (2008). Gimp, the GNU image manipulation program. Available at: http://www.gimp.org. [Accessed October 2012].
36. Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:332-336.
37. Nasrallah HA, Gopal S, Gassmann-Mayer C, Quiroz JA, Lim P, Eerdekens M, et al. (2010). A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 35:2072-2082.
38. Nesvag R, Tanum L (2005). Therapeutic drug monitoring of patients on risperidone depot. Nord J Psychiatry 59:51-55.
39. Orwin R (1983). A fail-safe N for effect size in meta-analysis. J Educ Stat 8:157-159.
40. Pandina GJ, Lindenmayer JP, Lull J, Lim P, Gopal S, Herben V, et al. (2010). A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J Clin Psychopharmacol 30:235-244.
41. Paulson JF, Bazemore SD (2010). Prenatal and postpartum depression in fathers and its association with maternal depression: a meta-analysis. JAMA 303:1961-1969.
42. Pramyothin P, Khaodhiar L (2010). Metabolic syndrome with the atypical antipsychotics. Curr Opin Endocrinol Diabetes Obes 17:460-466.
43. Riedel M, Strassnig M, Muller N, Zwack P, Moller HJ (2005). How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials? Eur Arch Psychiatry Clin Neurosci 255:143-148.
44. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. (2003). Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693-2702.
45. Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, et al. (2011). Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med 364:842-851.
46. Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, et al. (2012). Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 38:167-177.
47. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283:2008-2012.
48. Trikalinos TA, Churchill R, Ferri M, Leucht S, Tuunainen A, Wahlbeck K, Ioannidis JP (2004). Effect sizes in cumulative meta-analyses of mental health randomized trials evolved over time. J Clin Epidemiol 57:1124-1130.